Abstract: Objective To investigate the short-term efficacy and safety of vinorelbine plus cisplatin for anthracycline and(or) taxane-resistant metastatic triple-negative breast cancer. Methods Thirty patients with anthracycline and (or) taxane-resistant metastatic triple-negative breast cancer patients received vinorelbine and cisplatin regimen:vinorelbine 25 mg/m2，d1，d8;cisplatin 25 mg/m2 ，d2～d4.Treatments were repeated every 21 days and response rate was evaluated every two cycles. Results Complete remission(CR),partial remission(PR)，stable disease(SD) and progressive disease（PD） were 1 case(3.3%),16 cases(53.3%),10 cases(33.3%) and 3 cases (10.0%)，respectively.Objective response rate was 56.7%.The main adverse reactions were bone marrow suppression and gastrointestinal reactions. Conclusion Combination of vinorelbine and cisplatin was an effective and well-tolerated rescue regimen in anthracycline and(or) taxane-resistant metastatic TNBC patients.